ONC
BeOne Medicines Ltd. American Depositary Shares
About: Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Employees: 11,000
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
158% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 26
50% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 9 (+3) [Q1 2025]
43% more capital invested
Capital invested by funds: $8.06B [Q4 2024] → $11.6B (+$3.5B) [Q1 2025]
16% more funds holding
Funds holding: 223 [Q4 2024] → 259 (+36) [Q1 2025]
9% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 75
3% more call options, than puts
Call options by funds: $44.1M | Put options by funds: $42.9M
0.18% less ownership
Funds ownership: 3.49% [Q4 2024] → 3.31% (-0.18%) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$311
24%
upside
Avg. target
$326
30%
upside
High target
$350
40%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Sean Laaman | 32%upside $330 | Overweight Maintained | 27 Jun 2025 |
JP Morgan Jessica Fye | 28%upside $321 | Overweight Maintained | 27 Jun 2025 |
RBC Capital Leonid Timashev | 24%upside $311 | Outperform Reiterated | 27 Jun 2025 |
RBC Capital Gregory Renza | 24%upside $311 | Outperform Maintained | 8 May 2025 |
Guggenheim Michael Schmidt | 40%upside $350 | Buy Maintained | 8 May 2025 |
Financial journalist opinion
Based on 7 articles about ONC published over the past 30 days
Neutral
Business Wire
1 day ago
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasop.
Neutral
Business Wire
2 days ago
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies. Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen's RenMice® ful.
Neutral
Business Wire
2 days ago
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
BEIJING--(BUSINESS WIRE)-- #Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies. Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen's RenMice® ful.
Neutral
Business Wire
2 weeks ago
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today's investor R&D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage assets in development, a signal of both scale and ambition. “At BeOne, our mission is simple yet bold: to create t.
Neutral
Business Wire
2 weeks ago
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
BASEL, Switzerland--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of a new film-coated tablet formulation of BRUKINSA® (zanubrutinib) for all approved indications. The CHMP positive opinion will now be reviewed by the European Commission, which will grant the marketing authoriza.
Positive
Seeking Alpha
3 weeks ago
BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium
BEIGF recently rebranded to BeOne Medicines and relocated to Switzerland. It now operates a worldwide R&D and sales footprint across major oncology markets. Its main value driver is Brukinsa which accounts for 72% of their Q1 2025 revenues. There are continued label expansions planned as well. Tevimbra is its second growth engine, and BEIGF has full global rights outside China.
Neutral
Business Wire
4 weeks ago
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne's next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which ha.
Neutral
Business Wire
1 month ago
U.S. FDA Approves Tablet Formulation of BeOne's BRUKINSA® for All Approved Indications
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA® (zanubrutinib) for all five approved indications. BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all lines of therapy in the U.S., and for the first time, has become the overall BTK inhibitor market share leader.
Neutral
Business Wire
1 month ago
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will host an Investor R&D Day in New York City and via webcast on June 26, 2025 at 8:30 am ET. John V. Oyler, Co-Founder, Chairman, and CEO of BeOne, along with the Company's leadership team and distinguished key opinion leaders, will provide an update on BeOne's extensive global innovation pipeline and platforms, including new assets, targets.
Positive
Investors Business Daily
1 month ago
Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple
Cancer stock BeiGene renamed itself as BeOne. Shares have gained 40% year to date, outperforming the S&P 500.
Charts implemented using Lightweight Charts™